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Introduction
A fellowship curriculum is important in the training of a clinical cardiac electrophysiologist.
A clinical cardiac electrophysiology curriculum was first published in 2001 and was the
basis for education in many fellowship programs.1 Over the last 10 years cardiac
electrophysiology has continued to grow, evolve, and mature so that an update is currently
needed. This update is focused on what a practicing electrophysiologist will need in the care
of patient. It is not meant to be a mandatory education requirement or to supplant American
Board of Internal Medicine (ABIM) or Accreditation Council for Graduate Medical
Education (ACGME) requirements. Each section was written by one of the authors, but all
authors have reviewed the entire document.
1. Normal physiology
Fellows should possess an understanding of the basic anatomic, cellular and molecular
mechanisms of electrophysiology as they pertain to normal physiology. These concepts
include the cellular and molecular bases for electrical function of the heart under normal and
pathophysiologic conditions, anatomic relationships within the heart, the mechanisms
responsible for the development of arrhythmias, and the actions of antiarrhythmic drugs.
A. Anatomic structures, anatomic relationships and vascular supply2-5
1. Conduction system (sinus node, intranodal pathways, AV node, His
bundle and bundle branches, and Purkinje fibers)
2. Venous anatomy (superior and inferior vena cava, coronary sinus and its
branches, pulmonary veins)
3. Anatomy of great vessels (right and left ventricular outflow tracts)
including relationship to aortic sinuses of Valsalva and ostia of coronary
arteries
4. Autonomic nervous system, ganglionic plexi, and phrenic nerve
B. Resting membrane potential, action potential and passive membrane
properties2,6-10
1. Genesis of the resting potential in excitable cells
2. Active membrane properties
3. Cardiac action potentials (SA node, internodal tracts, atrial myocardium,
AV node, bundle of His, bundle branches, Purkinje fibers, ventricular
muscle)
4. Passive membrane properties
5. Channels and ionic currents responsible for the action potential (voltage
operated, pump and exchange currents, ligand operated,
mechanosensitive)
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6. Genes encoding for cardiac ion channels, exchangers, and pumps
7. Electrical heterogeneity
8. Mechanisms of automaticity in nodal and Purkinje pacemakers
9. Impact of drugs
C. Determinants of normal conduction2
1. Structure and function of gap junctions
2. Passive membrane properties and electrotonic interactions
3. Anisotropy
4. Modulation of these factors by sympathetic and parasympathetic agonists
5. Excitability, supernormality and vulnerability
D. Cellular basis for the inscription of the ECG11,12
1. P wave
2. QRS




1. Voltage-gated ion channels13
2. Ligand operated ion channels (include RyR)14,15
3. Connexins16
4. Regulation of ion channels in health and disease17,18
5. Ion channels as targets for genetic arrhythmia syndromes
6. Ion channels as anti- and pro-arrhythmic drug targets19,20
2. Genetic basis of arrhythmia
The heritable arrhythmia syndromes, also known collectively as the cardiac channelopathies,
represent an exciting and expanding discipline for electrophysiologists.21 Since heart rhythm
specialists are typically the primary caretakers for patients with heritable arrhythmia
syndromes and their families, the fellow needs to be familiar with the following:
A. The spectrum of heritable arrhythmia syndromes/cardiac channelopathies
including22:
1. Long QT syndrome (LQTS)
2. Brugada syndrome (BrS)
3. Catecholaminergic polymorphic ventricular tachycardia (CPVT)
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4. Short QT syndrome (SQTS)
5. Progressive cardiac conduction disease (PCCD)
6. Familial atrial fibrillation (FAF)
7. Inferolateral early repolarization syndrome
8. Commotio cordis23
B. The pathogenetic basis for the cardiac channelopathies including22,24:
1. Loss-of-function mutations in potassium channels (Kv7.1 and Kv11.1)
explaining two-thirds of all LQTS
2. Loss-of-function mutations in the sodium channel (Nav1.5) explaining
~25% of BrS with the majority of BrS still being genetically elusive
3. Mutations in the RYR2-encoded cardiac ryanodine receptor as the cause
for approximately two-thirds of CPVT
C. Genotype–phenotype relationships and risk stratification for each
channelopathy7,22,24,25
D. The state of genetic testing for each cardiac channelopathy including26-28:
1. Diagnostic, prognostic, and therapeutic implications
2. The yield of genetic testing
3. Distinguishing true pathogenic mutations from background genetic noise
4. The need for pre-genetic test counseling and acquisition of those skills or
partnership with genetic counselors and/or geneticists
E. The indications for pharmacotherapy, left cardiac sympathetic denervation therapy,
and device therapy for the cardiac channelopathies7,24,25
3. Diagnosis of arrhythmia
3.1: Surface ECG and ambulatory monitoring
Clinical Cardiac Electrophysiology Fellows should meet minimum competency
requirements of Cardiovascular Disease fellowship training for electrocardiogram (ECG)
interpretation as outlined by the American College of Cardiology Task Force. Fellows are
expected to be fully familiar with the indications and performance of a variety of
noninvasive ECG tests.
A. Surface ECG interpretation2,29-31
1. Evaluation of normal and abnormal intervals
2. Recognition of myocardial infarction and evidence of ischemia
3. Metabolic/drug effects with special attention to antiarrhythmic toxicity
(QT prolongation and conduction abnormalities)
4. Classification and mechanism of conduction disturbances and block
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5. Chamber hypertrophy or enlargement; ECG findings in athletes
6. Atrial and ventricular paced rhythm with recognition of:
• Site of pacing
• Failure of appropriate pacemaker function
• Mode of pacing; presence of biventricular pacing
7. Identification of accessory AV connection location, ventricular
tachycardia, atrial tachycardia location
8. Recognition of ECGs associated with clinical syndromes (long QT, short
QT, Brugada, ARVC/D, secundum ASD, Wolff-Parkinson-White, HCM,
myotonic dystrophy type I)
9. Fusion and capture beats
10. Identification of technical problems such as misplaced leads and artifact
B. Noninvasive ECG tests32-34
1. Ambulatory ECG recordings
2. Continuous on-line ECG monitoring (telemetry)
3. Mobile outpatient ECG monitoring with telephone-based telemetry
4. Identification of artifact, distinguishing artifact from arrhythmias
5. Manually and automatically activated event/loop/mobile cardiac outpatient
telemetry (MCOT) recorders with an understanding of the use of each
6. Analysis of signal-averaged ECGs
7. Exercise testing for the presence of myocardial ischemia and/or
arrhythmias; assessment of appropriate shortening of QT
8. Heart rate variability, heart rate turbulence and other ambulatory ECG
measures of autonomic balance as risk markers
9. T wave alternans as a risk stratifier
10. Indication for implantable loop recorders
C. Bradyarrhythmias
1. Abnormalities of sinus node function, including inappropriate sinus
bradycardia, sinus arrest, and sinus exit block
2. Abnormalities of AV conduction and their localization to the AV node,
His bundle, or His-Purkinje system
D. Tachyarrhythmias35-40
1. Recognition of atrial tachycardia, reentrant arrhythmias using manifest or
concealed AV connection pathways, and AV nodal reentrant tachycardias
(AVNRT)
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2. Localization of atrial tachycardia
3. Typical and reverse typical (isthmus dependent) atrial flutter, lesion
reentry, left atrial, and atypical flutters
4. Localization of re-entry in atypical flutter
5. Atrial fibrillation with particular reference to focal origins
6. Wide QRS complex tachycardia with special attention paid to
distinguishing VT from supraventricular tachycardia with aberrant
ventricular conduction and ventricular preexcited tachycardias
7. Special ventricular arrhythmias include:
• Ventricular ectopy with special attention to bigeminy and
parasystole as well as the quantification of beats over a 24-
hour period. Localization of ventricular ectopic beats within
the right and left ventricles, aortic cusp and epicardial
surface
• Nonsustained VT (monomorphic or polymorphic) with or
without associated long QT intervals
• Sustained VT with particular attention to idiopathic VT
versus tachycardia associated with organic heart disease
• Sustained polymorphic VT with or without long QT intervals
• Bidirectional VT and other drug-induced tachycardias
E. Miscellaneous arrhythmogenic situation30,31,39-41
1. LQTS; specific patterns of T waves related to gene defect
2. Brugada syndrome24
3. Arrhythmogenic right ventricular dysplasia30
4. Idiopathic ventricular fibrillation
• Short QT syndrome
• Early repolarization patterns40
5. Commotio cordis41,42
3.2: Invasive electrophysiological evaluation
Electrophysiology fellows should be able to list the indications for invasive
electrophysiologic studies; perform and interpret a comprehensive electrophysiologic study;
create and interpret an electroanatomic endocardial activation map; indicate the sensitivity
and specificity of these findings; integrate these findings into the clinical care of the patient,
use the information to formulate an ablation strategy when indicated.
A. Principles of multi-electrode catheter placement, electrogram recording, and
stimulation
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1. Techniques of intracardiac, multielectrode catheter placement in right-
sided chambers, and in left-sided chambers using coronary sinus,
transseptal, and retrograde aortic approaches
2. Genesis of the intracardiac recording
3. Types of recordings
• Unipolar
• Bipolar
- Effect of electrode spacing
- Effect of electrode orientation (linear,
orthogonal)
4. Filtering
• Bandpass and its effect on signal content
• Notch filter
5. Gain and clipping of recorded signal
6. Electrode field and concept of local activation time
7. Display of electrograms using a basic electronic electrophysiology
recording system. Understanding electrical connections and
troubleshooting of such systems
8. Principles of advanced three-dimensional mapping systems including
anatomical chamber reconstruction, image integration, and creation and
interpretation of electroanatomical and voltage maps43
9. Principles of stimulation
• Concept of pacing threshold
• Types of stimulation and implications for pace mapping
- Unipolar
- Bipolar
B. Sinus node, AV node and His-Purkinje system function44-46
1. Obtaining and evaluating the sinus node recovery time, and sinoatrial
conduction time
2. Intra-atrial versus AV nodal conduction disease
3. AV nodal function and dysfunction in response to atrial pacing
4. Diagnose conduction delay or block as within the AV node or His-
Purkinje system, and integrate this information with regard to need for
permanent cardiac pacing46
C. Supraventricular tachycardias (SVTs)
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1. Understand mechanisms and methods of induction of different SVTs
• Atrial fibrillation
• Atrial tachycardia and flutter
- Focal
- Macroreentrant
- Post left atrial ablation for atrial
fibrillation
• AV node reentrant tachycardia
• AV reentrant tachycardia
• Junctional ectopic tachycardia
2. Use of baseline observations, tachycardia features, and pacing maneuvers
to differentiate various forms of SVT47
D. Ventricular arrhythmias
1. Detail the number of sites and standard stimulation protocol for induction
of VT
2. Recognize the value of His-bundle and atrial recordings in the diagnosis of
VT and/or bundle branch reentry
3. Detail the sensitivity, specificity, and efficiency of induction protocols
with respect to clinical presentation (VT, sustained and nonsustained, or
ventricular fibrillation) and underlying myocardial substrate48
E. Principles of resetting and entrainment and termination of tachycardias49-51
1. Interpretation of resetting curves
2. Definition of entrainment
• Constant fusion during pacing at a constant rate faster than
the tachycardia except for the last captured beat that is not
fused
• Progressive fusion
• Interruption of tachycardia by overdrive pacing associated
with localized conduction block to a site followed by
activation of that site by the next pacing impulse from a
different direction and with a shorter conduction time
• Change in conduction time and electrogram morphology at
one recording site when pacing from another site at two
different constant pacing rates, each of which is faster than
the spontaneous rate of the tachycardia, but fails to interrupt
it (electrogram equivalent of progressive fusion)
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3. Techniques of entrainment
• Pacing technique and assurance of capture




4. Implications of entrainment
• Presence of reentry
• Significance for mapping
5. Recognition of termination without global capture
6. Identification of reentry circuit sites during catheter mapping and
radiofrequency ablation of ventricular tachycardia late after myocardial
infarction.
3.3: Laboratory safety
Electrophysiology trainees should understand principles of laboratory safety, with regard to
maximizing protection of patients, operators, and laboratory staff. Emphasis should be
placed on educating trainees in the use and effects of diagnostic radiation. Other categories
of laboratory safety include proper use of electrosurgical instruments, and prevention of
transmissible diseases.
A. Use and effects of ionizing radiation52
1. Principles of X-ray imaging
• Units and measurements of ionizing radiation
• Operation of X-ray equipment
• Procedures and X-ray settings for image acquisition
• Methods for dose reduction
2. Risks of X-ray imaging for patients
• Deterministic effects of X-rays (skin injury)
• Stochastic effects of X-rays (neoplasm)
• Follow-up of patients exposed to diagnostic radiation
• Managing X-ray exposure for pregnant patients
3. Risks of X-ray imaging for operators and staff
• X-ray protection protocols and techniques
• Monitoring of occupational radiation exposure and
regulatory limits
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• Precautions for medical employees during pregnancy
B. Safe use of electrosurgery in the electrophysiology laboratory
1. Electrosurgery in operative procedures
• Biological effects of electrosurgical waveforms
• Potential harm of electrosurgery - Tissue necrosis
- Improper grounding
- Interaction with operative environment
and protection of operative field
(flammable gasses)
• Interaction with implantable cardiac rhythm devices
2. Radiofrequency in catheter procedures53
• Biophysics of catheter ablation
• Factors affecting lesion formation
• Methods of delivering intracardiac radiofrequency energy
(solid electrode, irrigated, hybrid bipolar and unipolar)
• Risks of intracardiac radiofrequency energy (perforation,
thrombosis, volume overload)
• Risks of improper grounding pad placement
C. Precautions for transmissible diseases
1. Transmissible agents in invasive procedures (hepatitis B, hepatitis C, HIV)
2. Modes of transmission (injection, splash)
3. Risks of infection with different agents
4. Prophylaxis of infection among operators
• Precautions
• Post-exposure prophylaxis
4. Treatment of arrhythmia
4.1: Basic pharmacokinetics and pharmacodynamics
Pharmacokinetics and pharmacodynamics are essential concepts in understanding
therapeutic drug delivery. Although drugs are less commonly used clinically as a first-line
therapy for ventricular arrhythmias, they frequently are utilized as adjunctive therapy. In
addition, antiarrhythmic agents are frequently used for management of atrial fibrillation.
A. Basic pharmacokinetic principles54,55
1. Absorption
Link et al. Page 10






















2. Distribution, especially effect of heart failure and shock on central volume
of distribution
3. Metabolism, especially role of cytochrome P450 system and of p-
glycoprotein;
4. Positive and negative effects on these metabolic systems by other drugs,
diet, genetic variants
5. Elimination of drugs by liver, kidney, and lungs
B. Clinical pharmacokinetics
1. Drug interactions
2. Effect of age, gender, disease states
C. Pharmacodynamics
1. How drugs affect the body via receptors
2. Agonists and antagonists
D. Pharmacodynamics and pharmacokinetics of antiarrhythmic drugs
1. Utility and limitations of various classification schemes: Vaughan-
Williams, Sicilian Gambit, etc.
2. Effects of drugs on ion channels
3. Effects on conduction and refractoriness of atrial and ventricular
myocardium, bypass tracts, and His-Purkinje tissue
4. The following information for individual antiarrhythmic agents in normal
subjects and in patients with renal, hepatic, or heart failure or with





• Diagnosis and management of adverse effects10
• Pathways for metabolism and elimination
5. Range of expected elimination t1/2
Use dependence and reverse use dependence
E. Individual antiarrhythmic medications56,57
1. Class 1a: Quinidine, Disopyramide, Procainamide
2. Class 1b: Mexiletine
3. Class 1c: Flecainide, Propafenone
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1. Effect on pacing threshold and defibrillation efficacy
2. Effect on tachycardia cycle length and response to antitachycardia pacing
4.2: New technology/ablation physics
It is useful for fellows to understand the scientific basis of lesion formation during catheter
ablation. One should know the factors that affect the successful application of an ablative
lesion and learn how to modify those factors to yield safe and effective catheter ablations.
4.2.1: Biophysics of ablation—
A. Modes of tissue heating53,58-61
1. Electromagnetic spectrum
• Radiofrequency energy - resistive heating
• Microwave energy - dielectric heating
• Laser energy - photonic heating
• Direct (volume) heating of tissue
• Conductive heating to deeper tissue layers
2. Ultrasound ablation
• Mechanical heating of tissue
• Deep volume heating
3. Direct thermal ablation
4. No volume heating - highest temperature is at source
5. Conductive heating only
B. Factors that increase depth of tissue heating
1. Temperature of source
• Surface temperature limited to 100°C because of boiling and
coagulum formation
2. Power
3. Size of heat source
4. Duration of heating
C. Convective cooling
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3. Beneficial effects of surface cooling
4. Balance of cooling versus heating and power delivery
D. Cryothermic ablation61
1. Mechanism of refrigerant vaporizing at catheter tip
2. Cryoadhesion and ice ball formation
4.2.2: Pathophysiology of ablation—
A. Tissue effects of hyperthermia
1. Microvascular injury
B. Cellular effects of hyperthermia
1. Thermal poration of sarcolemmal membrane
2. Other organelle damage
C. Cellular effects of freezing and thawing
4.2.3: Technologies to create therapeutic ablative lesions—
A. Large tip RF electrodes58,62
B. Cooled tip RF electrodes
1. Internally-cooled
2. Perfused tip
C. RF array catheters
1. Circular
2. Mesh
D. Force sensing ablation catheter
E. Laser balloon ablation catheter
F. Hot balloon ablation catheter
G. Cryoballoon ablation catheter
4.2.4: Adjunctive technologies to facilitate catheter ablation—
A. Electroanatomic mapping systems
B. Intracardiac echocardiography
C. Robotic catheter manipulation
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Electrophysiology trainees should be aware of cardiac imaging modalities that aid diagnosis
of arrhythmia, as well as invasive management.63,64 The relevant imaging may be done
prior to an invasive procedure (ablation or device implant), online monitoring during the
procedure for complication and catheter guidance, as well as risk stratification and selection
of the appropriate procedure.
4.3.1: Intracardiac ultrasound examination65-67—
A. Fellows should be familiar with both rotational and linear phased array
B. Guidance for transseptal catheterization
C. Guidance for pulmonary vein isolation
D. Access to cardiac chambers in patients with congenital heart disease
E. Monitoring for complications, including thrombus and cardiac perforation
F. Guidance during papillary muscle VT ablation
G. Guidance during aortic cusp VT Ablation
4.3.2: Computerized tomography (CT) for heart and pulmonary veins68—
A. Use and evaluation for right ventricular dysplasia and structural abnormality in
patients with ventricular tachycardia
B. Pre- and post-ablation imaging for pulmonary vein morphology and detection of
pulmonary vein stenosis
4.3.3: Magnetic resonance imaging69-71—
A. Delayed gadolinium enhancement in dilated and hypertrophic cardiomyopathy for
risk stratification-sudden cardiac death/ventricular arrhythmia
B. Diagnosis of right ventricular dysplasia and other cardiomyopathies
C. MRI evaluation for congenital heart disease to aid catheter navigation and
identification of the arrhythmogenic substrate
D. Merging CT data with electrograms and other invasive electrophysiology data
4.3.4: Imaging to map electrical activation—
A. Electroanatomic mapping systems
B. Tissue Doppler evaluation
4.3.5: Ancillary imaging for invasive electrophysiology therapy—
A. Ventilation perfusion imaging, quantitative and qualitative for detecting pulmonary
vein stenosis
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B. Contrast echocardiography and advanced echocardiographic imaging to identify
substrate for ventricular arrhythmia
4.4: Ablation of SVT
Clinical electrophysiology fellows should understand which patients would be expected to
benefit from radiofrequency ablation of SVT. They should be confident in the laboratory
differential diagnosis of SVT and the techniques required for ablation. They should have
experience in the use of three-dimensional mapping systems, techniques for retrograde and
transseptal access, and should understand the underlying anatomy sufficiently to help to
avoid complications.
A. Patient selection and pre-procedure evaluation, including cardiac monitoring,
exercise stress testing, echocardiography and cardiac catheterization in selected
individuals
B. Equipment
1. Catheters types and associated curves
2. Sheaths, including curves and uses
3. Energy sources, including the indications for cryoablation
C. Anatomy72
1. Epicardial coronary vessels
2. Atrial anatomy
• AV node and His bundle






• Noncoronary sinus of Valsalva, and significance for atrial
ablation
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• Ablation of AVNRT
- Slow pathway (preferred method)
- Fast pathway
• Mapping techniques for radiofrequency ablation
- Slow potential guided
- Anatomically guided
• Relative accuracy of endpoints of ablation
- Noninducibility
- Junctional AV beats during ablation
- Elimination of slow pathway
function
2 AV reentrant tachycardia73-75,77,78





- Atypical bypass tracts
• Mapping techniques
- Anterograde activation mapping of
the earliest ventricular activity
- Retrograde activation mapping of the
earliest atrial activity
- Bypass tract potentials
• Left-sided approaches
- Transseptal
- Transaortic valve retrograde
3 Atrial tachycardia (focal and reentrant)79,80
• Most frequent sites of origin: Crista terminalis, eustachian
ridge, pulmonary veins, valve annuli
• Mapping, including intracardiac pace mapping, three-
dimensional mapping systems
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• Understanding of influence of prior surgery, atrial fibrosis
• Endpoints
E. Maneuvers to distinguish supraventricular tachycardia mechanism47,81-83
1. Classification schemes
• Long RP versus short RP
• Wide QRS complex versus narrow QRS complex
2. Maneuvers
• His refractory ventricular pacing (for narrow complex
tachycardia) and atrial pacing (for wide complex
tachycardia)
• Changes in tachycardia cycle length and VA time with
bundle branch block
• Para-Hisian pacing
• Tachycardia response after burst ventricular pacing
• Tachycardia response after burst atrial pacing (VA linking)
• Ventricular burst pacing during SVT to dissociate the atrium
from ventricle
• Evaluation of mode of initiation of SVT (critical AH delay)




5. Atrial fibrillation and flutter
Heart rate control and rhythm control with drugs remain the mainstay of therapy of atrial
fibrillation, however; it has become clear that when drug therapy fails to control symptoms,
this goal can be accomplished by ablation. Accumulating evidence that restoration of sinus
rhythm by ablation improves symptoms, cardiac function and exercise capacity in selected
groups of patients has led to large-scale morbidity and mortality trials, which are ongoing.
Even if these trials are ultimately negative, the major symptomatic benefits of restoration of
sinus rhythm by ablation suggests that competence endocardial ablation for atrial fibrillation
and atrial flutter has become a requirement for graduating EP fellows.
Anticoagulation with vitamin K antagonists (i.e., warfarin) remains the mainstay of stroke
prevention, although left atrial occlusion devices are likely to become clinically available in
the lifetime of this document. Most significantly, perhaps, alternatives to anticoagulation
with vitamin K antagonists have been developed, and a prototypical direct thrombin
inhibitor, dabigatran, is now approved in the US. Other direct thrombin inhibitors and direct
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1. Multiple reentrant wavelets versus single dominant rotor with fibrillatory
conduction
2. Pulmonary vein and non-pulmonary vein focal triggers for atrial
fibrillation
3. Importance of ganglionated plexi
4. Atrial remodeling
5. The renin-angiotensin-aldosterone system in atrial fibrillation
B. Epidemiology
1. Age associated prevalence – the demographic time bomb
2. Associated co-morbidities: Hypertension, ischemic heart disease, valvular
heart disease, congestive car-diac failure, heart surgery, obesity, sleep
apnea, other non-cardiac causes
C. Risks of atrial fibrillation87,88
1. Stroke and other arterial emboli
2. Tachycardia induced cardiomyopathy
D. Prevention of thromboembolism in atrial fibrillation
1. The trials of vitamin K antagonists in primary prevention of stroke in atrial
fibrillation; meta-analysis of these trials87,88
2. The CHADS2 score87,88
3. Use of aspirin, clopidogrel, and aspirin/clopidogrel combination
therapy89,90
4. Left atrial appendage occlusion devices
5. Direct thrombin inhibitors (e.g., dabigatran)91,92 and factor Xa inhibitors
(e.g., Rivaroxaban, apixaban)
E. Drug therapy for atrial fibrillation
1. Strategy selection: Suppression of atrial fibrillation (“rhythm control”)
versus control of the ventricular response (“rate control”). AFFIRM,
RACE, RACE-II and AF-CHF trials93-96
2. Selection of heart rate controlling drugs87,88,96,97
3. Selection of antiarrhythmic drugs87,88,97
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F. Cardioversion of atrial fibrillation
1. Transthoracic cardioversion
2. Chemical cardioversion, and drug facilitated DC cardioversion




• Pacing only of benefit in the context of sinus node
dysfunction
2. Endocardial catheter ablation99-105
• Pulmonary vein isolation: Segmental ostial isolation vs wide
area circumferential ablation86
• Ablation of complex fractionated atrial electrogram106-109
• Linear left atrial
• Ablation of ganglionated plexi110
• Isolation of the coronary sinus
• Isolation of the superior vena cava
• Novel ablation modalities: Bipolar radiofrequency ablation,
balloon cryoablation
• Pacing maneuvers to differentiate far-field from near-field
electrograms
• Pacing maneuvers to evaluate conduction block across left
atrial linear lesions
3. Epicardial and surgical treatment
• Cut and sew maze
• Adjunctive atrial fibrillation surgery
• Hybrid endocardial and epicardial atrial fibrillation
procedures
4. Indications for AV junction ablation and pacing




4. Pulmonary vein stenosis
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5. Phrenic nerve damage
6. Post-ablation atrial tachycardia and flutter
I. Diagnosis, evaluation and management of post-ablation atrial tachycardia
5.2: Atrial flutter
A. Classification of atrial flutter
• Classic, cavotricuspid isthmus dependent, atrial flutter – typical
(counterclockwise) vs reverse typical (clockwise)111
• Scar-mediated atrial flutter
- Post cardiac surgery, especially congenital heart
disease112
- Post ablation113
• Atypical (type II) atrial flutter – e.g., upper loop flutter etc.
B. Risks of atrial flutter
• Stroke and other arterial thromboembolism114
• Tachycardia-mediated cardiomyopathy
• Association with atrial fibrillation
C. Prevention of thromboembolism in atrial flutter
D. Drug therapy for atrial flutter
• Selection of heart rate controlling drugs
• Selection of antiarrhythmic drugs
E. Nonpharmacologic therapy
• Superiority of catheter ablation over antiarrhythmic drugs in classic atrial
flutter115,116
• Endocardial catheter ablation117
• Importance of bidirectional cavotricuspid isthmus conduction block in
long-term success in classic atrial flutter118
• Understanding of pseudo-block (slow conduction) and pseudo-conduction
(crista breakthrough)
6. Ablation of VT
Fellows should recognize the indications, patient selection, risks and anticipated benefits of
catheter ablation for ventricular arrhythmias associated with or without structural heart
disease. It is reasonable to expect a cure for the majority of patients with truly idiopathic
VT, whereas catheter ablation usually is palliative in organic heart disease, especially in
advanced ischemic and non-ischemic heart disease. A recent consensus document
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summarizes characteristics of ventricular arrhythmias as well as patient selection for
ablation, and ablation results.119
1. Idiopathic VT
A. Sites
1. Right ventricular outflow tract and pulmonary artery
2. Left ventricular outflow tract
3. Aortic cusps
4. Mitral and tricuspid annulus
5. Epicardial basal VT
6. Intrafascicular verapamil-sensitive reentrant tachycardia
7. Papillary muscles120
B. Mapping techniques121
1. Activation mapping and pace-mapping
2. Identification of Purkinje potentials, entrainment mapping
C. Approach: Transvenous right ventricular, retrograde aortic, transseptal,
coronary venous system, percutaneous epicardial approach
2. Catheter ablation for non-ischemic cardiomyopathy122,123
A. Myocardial VT
1. Mechanism: Reentry within the myocardium
2. Location: Basal left ventricle, epicardium, right ventricle
3. Ablation: Guided by pace-mapping, entrainment mapping,
isolated potentials
B. Bundle branch reentry124
1. Generally occurs in patients with diffuse conduction system
disease
2. Role of different maneuvers, comparison of HH and VV
intervals, postpacing interval
3. Catheter ablation of post-infarction VT125,126
A. Most appropriate as palliative therapy for frequent VT in patients with
implantable defibrillators
B. Potential role for prevention of ICD discharges
C. Mechanism is reentry using surviving myocytes within scar tissue
D. Mapping: Entrainment if hemodynamically tolerated, pace-mapping for
non-tolerated VTs, identification of isolated potentials
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4. Catheter ablation of frequent PVCs in patients with cardiomyopathy127 and PVC-
induced ventricular fibrillation (VF) or polymorphic VT128
A. Recognize the relation of frequent PVCs in cardiomyopathy that is
reversible with radiofrequency ablation. Ventricular fibrillation or
polymorphic VT triggered by PVCs can be controlled by ablation of the
initiating PVCs.
7. Pacemakers (include indications)
The principles and practice of cardiac pacing are core competencies for a cardiac
electrophysiologist.129 Fellows should fully understand the indications for temporary and
permanent pacing, their limitations, and how to combine them with other therapies. Fellows
should be technically proficient in placing, programming and troubleshooting such devices.
Knowledge of the biophysics of pacing, the bioengineering of pacemakers and how they
may be influenced by external devices and biophysical sources is also important.
A. Pathophysiology of various bradyarrhythmias, their etiology and natural
history130,131
B. Effects of pharmacologic, ablation and radiation therapy on sinus nodal, AV nodal
and His-Purkinje system function
C. Physiologic pacing, including pacing modes,132 effects of pacing on electrical and
mechanical function of cardiac chambers, prevention of unnecessary RV pacing,133
His-bundle,134 Bachmann’s bundle and septal/ventricular outflow tract pacing,
concepts of CRT-P.130 Data on comparative atrial pacing locations.135
D. Understanding pacing system technology
a. Leads (including electrode configuration, fixation, insulation, conductors,
and connectors)
b. Pulse generators (including batteries, circuitry, sensors, and function,
including monitoring)
c. Biophysics of pacing, including strength duration curves
d. Electronics; sensing/stimulation/defibrillation
i. Basic quantities (ampere, charge, coulomb, ohm, volt, hertz)
ii. Derived quantities (resistance, capacitance, battery capacity)
and Ohm’s Law
e. Knowledge of timing cycles, blanking and refractory periods
f. Sensors (motion/activity and minute ventilation)
g. Mode switching algorithms
h. Emerging pacing energy sources, devices, diagnostics and other
functionality
E. Temporary pacing130
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F. Permanent pacemaker indications130
G. Permanent pacemaker implantation (training program should provide sufficient
experience and resources to enable fellows to perform pacemaker implantation,
troubleshooting and interrogation)
1. Pre procedure planning, including decisions on conscious sedation,
periprocedural anticoagulation136 and antimicrobial agents137
2. Anatomic considerations, including normal and abnormal cardiac and
great vessel variations, and selection of subcutaneous or subpectoral
pocket locations
3. Venous access approaches including cephalic, subclavian or axillary veins,
and unusual situations requiring the internal jugular or iliac veins
4. Techniques to deal with limited venous access
• Upsizing sheaths in cases of venous stenosis, consideration
of balloon angioplasty or lead explantation to enable lead
delivery
• Tunneling
• Using existing leads to provide access into central veins138
5. Interpreting electrograms from pacing system analyzers139
6. Evaluation of sensing, pacing parameters and impedances
7. Radiation safety
8. Knowledge of alternatives to transvenous lead placement in congenital
heart disease, including epicardial and transatrial approaches
9. Intra-operative complication recognition and management
H. Radiology
1. Fluoroscopic views and lead locations
2. Post operative X-ray evaluation and identification of complications
I. Immediate post-procedure care; recognition and management of complications
J. Permanent pacemaker follow-up and troubleshooting140
1. Comprehensive knowledge of specific device and lead parameters, and
which are most applicable to specific clinical scenarios
2. 12-Lead ECG recognition of device function, malfunction and pacing site
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3. Experience of various follow-up approaches, including clinic-based
interrogation, familiarity with transtelephonic follow-up, and remote
monitoring data from various manufacturers141
4. Monitoring and application of adaptive algorithms such as auto capture,
minimization of ventricular pacing, selection of AV intervals
5. Optimization of AV and VV timing by use of device-based algorithms and
modalities such as echocardiography




2. Techniques and tools
i. Superior approach
ii. Femoral approach
iii. Powered and non-powered sheaths
iv. Snares
3. Complications
L. Device-device, device-drug, device-environmental (electromagnetic) interactions
M. Management in patients with terminal illness143
8. ICD and CRT
A training program in clinical cardiac electrophysiology should include sufficient technical
and clinical instruction in advanced device management to allow the fellow to provide
highly competent clinical assessment, patient selection, device implantation, and follow-up
of eligible patients. This applies to single and dual chamber ICDs, and CRT-D and CRT-P
systems. This includes the direct management of the patient with respect to cardiac
arrhythmias, the overall management of the patient including heart failure and the implanted
system management with respect to performance.
A. Technologic principles
1. Basic design of leads, generators and programmers144
i. Shock coils and shock vectors
ii. Integrated vs dedicated bipolar design
2. Understanding of the function of the ICD/CRT system
3. Defibrillation waveforms (tilt and pulse width)
4. Programming principles
5. Detection and discrimination algorithms/enhancements
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6. Diagnostic storage capabilities
7. Physiologic monitor parameters
B. Indications for the ICD/CRT system and appropriate integration of results of
prospective trials into clinical decision-making145-148
C. Guidelines for implantation of ICD/CRT systems: American College of
Cardiology/American Heart Association (ACC/AHA)/(HRS)147,148
D. Implantation techniques and testing of ICD/CRT system function at
implantation130
a. Intra-operative defibrillation testing (DFT)
b. Defibrillation probability curve
E. Indication and implantation of coronary sinus leads to enable biventricular
pacing149-152
F. Drug-ICD interaction, including drug management at the time of implantation
G. Implant procedure complications, including subsequent wound management
H. Follow-up and troubleshooting, including awareness of device and lead
performance measures and advisories/recalls
I. Recommendations for driving for the patient153,154
J. Cost-effectiveness of the ICD/CRT system
K. Quality of life and psychosocial impact of the ICD/CRT system
9. Special conditions
9.1: Syncope
The evaluation and management of patients with unexplained syncope is an important
component of electrophysiology fellowship training. The fellow must understand the
guidelines for hospitalization,155,156 develop a strategy to identify a cause of syncope,155-159
and effectively risk stratify patients.155,157,160-162 Prolonged electrocardiographic (ECG)
monitoring is an important diagnostic tool in some patients.159 Patients with structural heart
disease are increasingly being treated with an implantable cardioverterdefibrillator (ICD);
however, mortality remains high in these patients.155,161,162
A. Epidemiology and prognosis155,157,160-162
B. Value of history, physical examination, electrocardiogram, and evaluation for
underlying structural heart disease155
C. Utility of syncope units
D. Classifications155,162
1. Neurally mediated syncope
2. Disorders of orthostatic hypotension and orthostatic intolerance
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E. Value of diagnostic tests, including tilt table tests, short and long-term ECG
monitoring, and electrophysiologic testing155,159,162
F. Treatment130,155
1. Lifestyle measures





1. Arrhythmogenic right ventricular cardiomyopathy163
2. Brugada syndrome
3. Congenital long QT syndrome164,165
4. Hypertrophic cardiomyopathy166
9.2: Sudden cardiac death
It is important for electrophysiology fellows to recognize the magnitude and different
mechanisms that underlie sudden cardiac death (SCD). Fellows should be cognizant of the
different precipitants of arrhythmias; comprehend evidence-based strategies for managing
patients who are survivors of SCD; understand the pharmacological and
nonpharmacological approaches of managing patients at risk for SCD; and grasp the
different risk stratification strategies to predict and prevent SCD. Fellows should be up to
date with all the completed clinical trials in this area while being aware of the most
important studies nearing completion.




B. Mechanisms of sudden death147,170
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- Ventricular tachycardia/ventricular fibrillation
- Torsades de pointes171
- Bradyarrhythmias
2. Channelopathies
- Long QT syndromes172,173
- Short QT syndromes
- Brugada syndrome174
3. Other genetic defects175
-Arrhythmogenic right ventricular dysplasia30,163
-Hypertrophic cardiomyopathy176
-Catecholaminergic polymorphic ventricular tachycardia
-Early repolarization syndrome40








3. Autonomic nervous system178
4. Congestive heart failure
5. Drug-induced proarrhythmia (e.g., long QT, digitalis toxicity, etc.)171
D. Management
1. ACLS guidelines179,180
2. Evaluation and therapy of structural heart disease and ischemia, including
echocardiography, exercise testing, cardiac catheterizations, CT and MRI
3. Role of electrophysiological testing181
4. Role of pharmacological therapy
5. Role of ICD therapy
6. Role of catheter ablation and surgical therapies
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7. Role of ancillary therapies (i.e., neurohormonal modulation, anti-ischemia,
autonomic blockade etc.)178
E. Risk stratification
1. Role, sensitivity and specificity of programmed ventricular stimulation in
patients with reduced left ventricular ejection fraction with and without
coronary artery disease181,182
2. Role, sensitivity and specificity of heart rate variability, signal-averaged
electrocardiography, T wave alternans, heart rate turbulence, QT interval
dispersion to prognosticate risk in certain subsets of patients32
3. Specific issues in athletes, including patient evaluation and limitation of
activities183,184
4. Provocative maneuvers in patients with possible genetic ion channel
abnormalities
5. Specific considerations in patients with hypertrophic
cardiomyopathy176,185
F. Completed clinical trials




5. Antiarrhythmics Versus Implantable Defibrillators (AVID) trial,189
Cardiac Arrest Study Hamburg (CASH)190 and Canadian Implantable
Defibrillator Study (CIDS)191
6. MASTER Trial
10. Insight on ABIM
When a constituent body of the American Board of Medical Specialties (ABMS), such as
the American Board of Internal Medicine, decides that a specialty area has matured
sufficiently, the Board establishes an examination in that field and prescribes the body of
knowledge that will be covered by the examination. In a somewhat analogous fashion, the
Accreditation Council for Graduate Medical Education (ACGME) then directs one of its
Residency Review Committees (RRC) to establish the standards to determine whether a
given hospital or other learning center can provide the necessary resources to provide the
prescribed education. The ACGME provides a learning philosophy (presently the “six
competencies”) and accreditation of teaching sites is based on whether such sites, including
staff, faculty, and trainees, are performing satisfactorily with respect to the six
competencies. The ACGME makes these determinations based on standardized self-study
forms (Program Information Forms) from each site, and an exhaustive site visit that is
carried out at intervals that depend largely on the overall track record of a given site, and
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how well the site has responded to citations from previous reviews. All of this takes a lively
interaction among many interested parties, including professional societies such as the Heart
Rhythm Society and the American College of Cardiology, the “House of Medicine”
(American Medical Association), hospitals (American Hospital Association), and primary
specialty groups (e.g., American College of Physicians-ACP). All of these are advisory.
The ABIM is definitive when it comes to the qualifications of an individual to sit for the
boards. The ACGME through its RRCs is definitive when it comes to certifying a site as
capable of providing the necessary learning experience. Many cardiology fellows and CCEP
fellows believe that the ACC’s Core Cardiology Training (COCATS) criteria are definitive;
although influential, they are not definitive. The Residency Review Committee’s criteria are
definitive and differ somewhat from both the current ABIM and COCATS criteria.
At the time of first approval, the knowledge and experience base needed to sit for the board
exams are determined by the ABIM. Thereafter, it is an iterative process. At the present
time, the ABIM is funneling its energies into changing over from the concept of a test every
10 years to an ongoing maintenance of certification process that emphasizes lifelong
learning. Thus, the RRC’s proposed program requirements for clinical cardiac
electrophysiology have more detailed and stricter electrophysiology procedure requirements
than those of the ABIM. However, this does not pose a problem because one must be a
graduate of an ACGME-approved program to sit for the ABIM boards.
ABIM PROCESS: The main component is the educational philosophy of lifelong learning,
which is part of the evolution from certification to recertification to maintenance of
certification. For each of the areas for which there is a board examination or “added
qualifications” exam, a committee of experts is convened. This committee also contains
educational philosophers and psychometricians. Together, they develop an examination
designed to test the relevant body of knowledge in as fair and scientific a method as
possible. The physician experts are usually well known in their respective field and they
bring with them information from their professional bodies, the literature, and their own
experience.
The ACGME has RRCs for the broad specialties. For example, there is an RRC for internal
medicine that certifies the training programs for the core internal medicine training
programs, all the subspecialties (in this case cardiology) and all the “sub-subs,” e.g., CCEP.
The ACGME provides broad umbrella requirements that extend to all major specialties
(Surgery, Pediatrics, Internal Medicine, etc.), and the respective RRCs use these broad
guidelines to develop the specific and detailed guidelines for each training program. Thus,
program directors in CCEP need to look at the “common program requirements” and the
respective program requirements for Internal Medicine and Cardiology, as well as those for
CCEP. The subspecialties do not exist in a vacuum, but must be in an overall milieu, which
includes a core internal medicine program, and several specialties with close communication
from the various program directors. For each program, the RRC determines many of the
details, such as minimum faculty, procedure volumes, conferences, continuity clinic, etc.
Again, following the ACGME philosophy, the RRCs are charged with ensuring that the
programs and the learners are all imbued with the concept of the six competencies. Indeed,
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outcomes are judged largely by assessment of how well the six competencies have been
achieved by the residents and fellows at the time of completion of their program.
Input through the RRCs comes from many sources. The RRC leads many patterns each year,
with agendas that include evaluation of programs based on self-study and site visits and
other meetings at which strategy, tactics, and updates are the primary items on the agenda.
The internal medicine RRC is comprised of five generalists and two physicians from each of
the specialties. At the present time, the author represents cardiology broadly and
electrophysiology in particular. There is another nonelectrophysiology cardiologist on the
committee. A subcommittee of the RRC establishes the program requirements for each of
the subspecialties and sub-subs. Each RRC meeting is also attended by staff, some of whom
are specifically assigned to the internal medicine RRC, and by others who represent the
general ACGME. Further, there are ex official members, nonvoting, representing the ABIM,
American Medical Association, and American College of Physicians.
Input for determination of requirements for internal medicine and all its subs and sub-subs is
reported to a subcommittee of the RRC, which establishes proposed requirements. Input can
come from any source, ranging from the literature to special advisory groups such as co-
cats, the ABIM, etc. The RRC is in the position of having authority over all internal
medicine training programs in the United States. It, therefore, recognizes the variation that
can exist; thus, some requirements may differ from those proposed by professional
organizations. In some cases, promulgation of such “ideal” requirements would endanger the
certification of a number of otherwise strong training programs. The reader of program
requirements must also be aware of the RRC “coded language,” in which “suggests” means
“it would be a very good idea,” “should” means “you really ought to do it or tell us why,”
and “must” means “just do it.”
SUMMARY
The ABIM is definitive for the individual, and the ACGME/RRC is definitive for programs
(Figure 1). There is some overlap in a Venn diagram fashion between the areas covered by
these two definitive organizations. Other bodies, organizations, or ideas are advisory only.
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Trainee learning experience. Interaction between the trainee, training site, and the various
organizations such as COCATS (ACC’s Core Cardiology Training), ABMS (American
Board of Medical Specialties), ABIM (American Board of Internal Medicine), AAMC
(Association of American Medical Colleges), AMA (American Medical Association),
ACGME (Accreditation Council for Graduate Medical Education), APDIM (Association of
Program Directors in Internal Medicine), RRC (Residency Review Committees).
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